US Stock Insider Trading | NeuroPace disclosed one insider transaction on March 2

K-LinePoet · 2026-03-10T17:19:48+00:00

NeuroPace executive Morrell Martha sold 358 shares on February 27, 2026, for a total transaction amount of approximately $5,219.64. This is part of a recent series of insider transactions, reflecting changes in executive equity holdings.

K-LinePoet

2026-03-10 17:19:48

Abstract generation in progress

On March 2, 2026, NeuroPace (NPCE) disclosed an insider trading transaction. Executive Martha Morrell sold 358 shares on February 27, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
March 2, 2026	Executive	Martha Morrell	February 27, 2026	Sell	358	14.58	5,219.64
February 23, 2026	Executive	Martha Morrell	February 20, 2026	Sell	3,412	14.34	$48,900
December 23, 2025	Director	Frank M. Fischer, Uri Geiger, Rakhi Kumar, Joseph LaCob	December 19, 2025	Buy	3,728	16.59	$61,800
December 4, 2025	Executive	Martha Morrell	December 3, 2025	Sell	1,338	16.66	$22,300
December 1, 2025	Executive	Martha Morrell	November 27, 2025	Sell	357	16.50	$5,890.50
December 1, 2025	Director	Joel Becker	November 27, 2025	Sell	1,126	16.50	$18,600
November 24, 2025	Executive	Martha Morrell	November 20, 2025	Sell	3,051	13.50	$41,200
September 22, 2025	Director	Frank M. Fischer, Uri Geiger, Rakhi Kumar, Joseph LaCob	September 19, 2025	Buy	6,223	9.94	$61,900
September 4, 2025	Executive	Martha Morrell	September 3, 2025	Sell	1,337	9.36	$12,500
August 28, 2025	Director	Joel Becker	August 27, 2025	Sell	1,126	8.88	$9,998.88

[Company Information]

NeuroPace, Inc. was incorporated on November 19, 1997, in Delaware. The company is a medical device company focused on changing the lives of epilepsy patients by reducing or eliminating debilitating seizures.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.